Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Non-Randomized Phase I Study of the Protein Kinase C Inhibitor Bryostatin-1 Administered in Combination With Paclitaxel in Patients With Advanced Solid Tumors

NCT00003242 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT00003242
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003242 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Non-Randomized Phase I Study of the Protein Kinase C Inhibitor Bryostatin-1 Administered in Combination With Paclitaxel in Patients With Advanced Solid Tumors
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 1
Overall status
Completed
Start date
February 28, 1998
Completion date
October 31, 2001
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

unspecified adult solid tumor, protocol specific